A low risk of TfR crosslinking with an antibody that binds both TfR and its therapeutic target bivalently, provides both high BBB transcytosis at low and high antibody concentrations, as well as avidity-enhanced engagement with aggregated targets such as Aβ protofibrils in Alzheimer’s disease. This evidence concerns the gene TFRC and Alzheimer disease.